read latest announcement, this biotech is in the same boat as pxs and cst, quality technology and management, although i believe it is grossly undervalued atm.I hold.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%